SUMMARY This study compares the clinical and serological differences between 17 PSS and 17 carefully matched CREST patients. Patients were matched for sex, age by decade, and, importantly, disease duration (112± 9.2 vs. 12*0±9-3 years). Muscular and skin involvement were greater for the PSS groups (p<002) and pulmonary involvement was also greater (p<0O05), at least for non-smoking PSS patients. On the other hand no clinically significant differences were found between groups for other visceral involvement -including comparisons of gastrointestinal, cardiovascular, and renal involvement. There were also no laboratory differences except in anti-RNP antibody (p<0-04).
Eight patients met all five criteria: six patients met four criteria, and three patients met three criteria. Sclerotic skin involvement was limited to the fingers in the CREST syndrome patients. In fact, the presence or absence of the major criterion for PSS (i.e., proximal scleroderma) separated our groups. Further, no CREST syndrome patient had any other definable rheumatological disease. The presence or absence of visceral involvement was not considered when we selected the CREST syndrome population.
The patients in the CREST syndrome group were involved in prospective studies at UCLA or were followed after a complete comprehensive diagnostic examination. Although no CREST patient met the major criterion for PSS, 12 met minor criteria (Table 1) . Seven had sclerodactyly and pitting scars (two also had fibrosis on chest x-ray), and five others had sclerodactyly and pulmonary fibrosis but no pitting scars. Five CREST patients did not meet criteria for PSS.
We screened over 150 prospectively followed up patients with systemic sclerosis and its variants to find 17 CREST syndrome patients as defined in this study. These 17 CREST patients were then matched to 17 PSS patients for sex, age, and disease duration. Further, perhaps because we are part of a tertiary 794 care facility, we found few CREST syndrome patients with disease duration less than five years from the first symptom (Table 1) .
PSS PATIENTS
The 17 PSS patients had sclerodactyly and also had sclerotic skin changes proximal to the MCP joints, thus satisfying the major ARA criterion for that disease' (Table 1) .
The PSS patients (who were enrolled in prospective studies of PSS at UCLA), were matched to the CREST patients by sex (one male and 17 females in each group), age by decade (48-2±10-9 (SD) vs. 49-5±10-9 years), and disease duration from first symptom (11.2±9.2 vs. 12-0±9-3 years). The first symptom was Raynaud's phenomenon in most cases.
DIAGNOSTIC TESTS
The studies done for evaluation of organ involvement included a history, a physical examination including a graded skin index, chest x-ray, electrocardiogram (ECG), treadmill, echocardiogram, cine oesophagogram with small bowel follow-through, barium enema, faecal fat determination, x-rays of the hands and feet, pulmonary function tests with spirometry, lung volumes, diffusing capacity and compliances, serum creatinine, serum creatine phosphokinase (CPK), electromyogram (EMG), and 24-hour urine for creatinine and protein.
Immunological tests included antinuclear antibody (ANA) using rat liver as substrate, latex fixation for rheumatoid factor, anti-ribonuclearprotein (RNP) and anti-Sm by haemagglutination, third component of complement (C3), antibody to single-stranded DNA (anti-ss-DNA), and quantitative immunoglobulins, all as routinely done in the UCLA Clinical Laboratories.
The organ systems tested included skin, kidneys, upper and lower gastrointestinal tract, joints, muscles, general cardiac, right heart, left heart, and pulmonary.
Several tests relating to any organ or organ system were done to define whether (and how much) that organ system was affected by disease (see Appendix A). For degree of involvement, objective tests or examinations were used whenever possible, and tests were weighted according to their estimated clinical importance. Frequently this approach resulted in conservative estimates of involvement. For 
Results
The patient's characteristics are outlined above, and the similar ages and disease duration indicated that matching was quite good. Table 1 shows the number of CREST criteria found for each patient in both groups. In the CREST group 14 out of the 17 patients met at least four criteria. Twelve of the 17 patients with CREST had PSS also, all by minor criteria. This contrasts with the control group, all of whom had PSS by the major criterion. Table 2 summarises the concordance of organ involvement in the two patient populations. In the 10 systems evaluated no differences were noted except for muscular involvement (p<0-06). More PSS patients had myopathy, defined by CPK and EMG (see Appendix A), while none had myositis. Thus in terms of the presence of organ involvement there involvement was different by definition (p<0-001). had more severe myopathy than the CREST group The tendency for a difference in the presence of (p<0-05). Further, non-smoking PSS patients had muscular involvement between the two groups more severe pulmonary involvement than their (p<006) was supported by the degree analysis CREST syndrome counterparts (p<0-05); in con-(Appendix A), which showed that the PSS patients trast, smoking PSS and CREST patients did not tRefers to the matching of patient pairs for presence or absence of organ involvement from Appendix A (e.g.. for pulmonary involvemcnt.
12 pairs of patients were concordant for presence or absence of pulmonary disease, two sets of patients werc seen wherc the CREST patients had pulmonary disease. and the PSS patient did not and three sets werc secn which were vice vcrsa). Table 4 displays the serological variables that were measured. As can be seen, there were usually no differences between the two groups. Latex fixation and ANA were positive in a high percentage in both groups and even anti-single stranded-DNA was abnormal in 15% of the cases. There were no instances of decreased C3 and no differences between the two groups in immunoglobulin G, M, or A concentrations. In fact, only anti-RNP was different in our comparisons (p<004).
Although none of the PSS patients were RNP positive, five of the 17 CREST patients had anti-RNP in their serum. All titres were greater than 1:2048, by haemagglutination. These five RNP group.bmj.com on May 1, 2017 -Published by http://ard.bmj.com/ Downloaded from positive CREST patients did not meet criteria for any other rheumatological disease. As expected, their ANA were positive (titres 1:640 to greater than 1:10 240). Rheumatoid factor was negative in two and anti-ss DNA was not raised in any. There were no erosions on x-ray, rashes, or myositis. Pulmonary hypertension was noted by right heart catheterisation in two out of these five patients and accentuated P2, pulmonary fibrosis, and/or decreased diffusing capacity was found in three patients (including the above two with pulmonary hypertension). Renal disease was found in one patient (creatinine clearance 54 ml/min; 24 h urine protein 900 mg/24 h) and gastrointestinal involvement (oesophageal stricture and duodenal dilatation) was found in two patients. The RNP positive CREST patients did not differ statistically from the RNP negative patients with respect to the degree or presence of organ involvement or in other serological abnormalities. The 12 CREST patients with minor criteria for PSS were also not different clinically or serologically from the five CREST patients who did not have PSS by any criteria.
Discussion
Although the CREST syndrome was first described in 1911 and again described in 1964, it was only in 1973 that oesophageal involvement was added to it.9-' The CREST syndrome is sometimes considered a more benign variant of PSS,2-4 but other authors emphasise that visceral involvement, including pulmonary hypertension, can occur.5 6 In a previously published report comparing CREST syndrome with PSS the CREST patients frequently had acrosclerosis; thus they had PSS by the major ARA criterion.7 Our study specifically excluded any patients from the CREST group who had hide-bound, sclerotic skin proximal to the MCPs, while all PSS patients met this major criterion. The PSS group was matched to the CREST patients with respect to age, sex, and, most importantly, duration of disease from first symptom.
The only clear difference with respect to the presence of organ involvement was myopathy (see Appendix A), where more PSS patients had myopathy than did CREST patients.
When examining the degree of organ involvement, skin involvement was different (by definition), and muscular involvement was again greater in the PSS group.
Shortness of breath, fibrosis on chest x-ray, diffusing capacity (DLco), forced expiratory volume in one second (FEVI), forced vital capacity (FVC), total lung capacity (TLC) and compliance were all determined during pulmonary testing. Shortness of breath and fibrosis were included in the pulmonary evaluation, and given increased weights, because they are clinically important (Appendix A). The five measured pulmonary functions are not necessarily independent estimates, so various measurement combinations were tested to ascertain if such combinations altered the results. In accordance with previous reports the diffusing capacity was found to be a sensitive indicator of pulmonary disease. 12 Since many combinations of measurement (e.g., FEVy + TLC + DLco + compliance; DLco + TLC, DLco + FEVI, etc.) were examined but did not change the results, the DLco was the single pulmonary function test used for the pulmonary evaluation. With shortness of breath and fibrosis on chest x-ray it made up the elements used to define the degree of pulmonary involvement (see Appendix A). Non-smoking PSS patients had more severe pulmonary disease than their non-smoking CREST syndrome counterparts (p<0.05). Smoking made both groups' lung disease worse but obscured the differences between groups, for no differences in pulmonary involvement were found when the smokers in each group were compared. No other differences were found for the seven other systems tested (upper gastrointestinal, lower GI, general cardiac, left heart, right heart, skeletal, and renal). When no statistical differences are found, power calculations estimate the assurance that false negatives did not occur. High power estimates ensure against false negatives. On the other hand low power estimates sometimes mean that large numbers of patients are needed because differences between patient groups are small (i.e., if we need large numbers of patients to achieve a given power, then the differences between patient groups are probably quite small, given reasonable standard deviations).
In our study the power estimates were high for skeletal and upper GI involvement, thus ensuring against false negatives. However, power estimates were modest for other organ systems tested. When we calculated the number of patients needed to achieve 80% assurance against a false negative (power=0-8) for the latter organs, we found that at least 66 matched patients were required for lower GI and right heart evaluations; 90-110 matched patients were needed for renal and left heart involvement; and over 3100 patients were required for general cardiac and pulmonary evaluations (smokers only). With such large populations needed to satisfy power requirements, we concluded that, in most of the latter categories, any potential differences were probably quite small and not prognostically significant for an individual patient.
Disease duration was calculated from the patient's first symptom, not from the date of diagnosis. Thus our patients' disease appeared to be of longer standing than if we had chosen the date of diagnosis for the 'beginning' of their disease. While we prospectively followed up over 150 patients with systemic sclerosis or its variations, only 17 had CREST by our definition and only five had their disease for less than five years (Table 1) . Perhaps this is because, as a tertiary care facility, we do not see patients with early disease. Thus the mean disease duration from first symptom in our CREST patients was 12 years. The five CREST patients with disease duration of less than five years had visceral involvement comparable to the CREST patients with longer-standing disease. Had we been able to compare patients with very early disease, the results might have been slightly different, but this comparison was not possible. In addition, because the survival rate of PSS patients has been reported to be only 45%,13 whereas it is still possible that survival of CREST patients may be somewhat better, the survivors who were available for enrolment in our study (a mean of 12 years after first symptoms) may represent a subgroup who did not develop early lethal organ system involvement.
In this population of patients anti-RNP was not a particularly reliable prognostic sign, as the anti-RNP positive CREST patients were not different from the anti-RNP negative CREST patients. No PSS patients were anti-RNP positive. It should be emphasised that none of the anti-RNP positive patients met criteria for any other rheumatic disease.
In summary, our CREST patients without the skin involvement proximal to the MCPs have cardiac, renal, skeletal, and gastrointestinal morbidity that is not very different from that of carefully matched PSS patients. Even if there are differences in any of the above systems, those differences are not large enough to be prognostically significant. Pulmonary involvement, at least for non-smokers, is less in CREST syndrome patients. The PSS patients, on the other hand, have more muscular involvement than the matched CREST patients. No serological differences, except for anti-RNP, were noted between the two populations.
